12,372 trials
Migraine · Headaches
Primary: Mean Sum of Migraine Pain Intensity Differences (SPID)-30 — 10.80; 7.41 scores on a scale — p=<0.0001
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason — 18.4; 20.1; 24.6 percentage of participants — p=0.017
Relapsing-Remitting Multiple Sclerosis
Primary: Number of Participants With Anti-DAC HYP Binding Antibodies (ADAbs): Electrochemiluminescent (ECL) Anti-Drug Antibody (ADA) Assay — 78; 35; 92; 21 participants
Differentiated Thyroid Cancer
Primary: Progression-Free Survival (PFS) — 10.0; 5.7 months — p=0.080
Psoriasis
Primary: Percentage of Participants With Treatment Success According to the Investigator's Global Assessment (IGA) — 21.50; 7.4 percentage of subjects
Rheumatoid Arthritis
Primary: Number of Participants With an Improvement in Bone Edema/Osteitis on Low-field MRI in Rheumatoid Arthritis Patients on Weekly SC Abatacept in Combination With…
Plaque Psoriasis · Psoriatic Arthritis · Pustular Psoriasis (Excluding a Localized)
Primary: Percentage of Patients Achieving 75% Improvement in the Psoriasis Area and Severity Index (PASI) Score — 0.0; 0.0; 0.0; 0.0 percentage of participants
NSCLC (Non-small Cell Lung Cancer)
Primary: Progression-Free Survival (PFS) Based on IRR by Treatment Arm — 11.1; 6.8 Months — p=<0.0001
Alpha₁-Antitrypsin Deficiency
Primary: AUC(0-7 Days) Based on Antigenic Content — 203.20; 198.38 mg*h/mL
Systemic Juvenile Idiopathic Arthritis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs by Severity, AEs Leading to Discontinuation, SAEs Leading to Discontinuation…
Brain Tumors · Metastatic Disease
Primary: Memory as Quantified by HVLT-immediate Recall — 22.5; 22.2 units on a scale — p=.62
Epilepsy · Generalized Tonic-clonic Seizures
Primary: Incidence of Treatment Emergent Adverse Events During the Entire Study Period — 626 Treatment Emergent Adverse Events
Influenza
Primary: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies Titers Against the 4 Vaccine Strains. — 253.2; 235.5; 73.6; 78.6 Titers
Juvenile Idiopathic Arthritis
Primary: Change in Pain Intensity — 3.56; 3.26; 3.07; 2.90 Units on a scale — p=<.001
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Participant Hemoglobin A1C Level at Week 24 — -1.28; -1.30 Percent A1C